Paragangliomas of the Head and Neck Local Control and Functional Outcome Following Fractionated Stereotactic Radiotherapy

被引:9
|
作者
Weissmann, Thomas [1 ]
Lettmaier, Sebastian [1 ]
Roesch, Johannes [1 ]
Mengling, Veit [1 ]
Bert, Christoph [1 ]
Iro, Heinrich [2 ]
Hornung, Joachim [2 ]
Janka, Rolf [3 ]
Semrau, Sabine [1 ]
Fietkau, Rainer [1 ]
Putz, Florian [1 ]
机构
[1] Friedrich Alexander Univ Erlangen Nuremberg, Dept Radiat Oncol, Univ Str 27, D-91054 Erlangen, Germany
[2] Friedrich Alexander Univ Erlangen Nuremberg, Dept Otorhinolaryngol Head & Neck Surg, Erlangen, Germany
[3] Friedrich Alexander Univ Erlangen Nuremberg, Dept Radiol, Erlangen, Germany
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2019年 / 42卷 / 11期
关键词
paraganglioma; fractionated stereotactic radiotherapy; tumor control; functional outcomes; volumetric analysis; LONG-TERM OUTCOMES; VESTIBULAR SCHWANNOMA; RESPONSE EVALUATION; VOLUME CHANGES; GLOMUS TUMORS; SKULL BASE; RADIOSURGERY; MANAGEMENT; DIAGNOSIS; SURGERY;
D O I
10.1097/COC.0000000000000614
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: To investigate local control and functional outcome following state-of-the-art fractionated stereotactic radiotherapy (FSRT) for paragangliomas of the head and neck. Methods: In total, 40 consecutive patients with paragangliomas of the head and neck received conventionally FSRT from 2003 to 2016 at the Department of Radiation Oncology of the University Hospital Erlangen. Local control, toxicities, and functional outcome were examined during follow-up. In total, 148 magnetic resonance imaging studies were subjected to longitudinal volumetric analysis using whole tumor segmentation in a subset of 22 patients. Results: A total of 80.0% (32/40) of patients received radiotherapy as part of their primary treatment. In 20.0% (8/40) of patients, radiation was used as salvage treatment after tumor recurrence in patients initially treated with surgery alone. The median dose applied was 54.0 Gy (interdecile range, 50.4 to 56.0 Gy) in single doses of 1.8 or 2 Gy. Local control was 100% after a median imaging follow-up of 52.2 months (range, 0.8 to 152.9 mo). The volumetric analysis confirmed sustained tumor control in a subset of 22 patients and showed transient enlargement (range, 129.6% to 151.2%) in 13.6% of cases (3/22). After a median volumetric follow-up of 24.6 months mean tumor volume had diminished to 86.1% compared with initial volume. In total, 52.5% (21/40) of patients reported improved symptoms after radiotherapy, 40% (16/40) observed no subjective change with only 7.5% (3/40) reporting significant worsening. Conclusions: State-of-the-art FSRT provides excellent control and favorable functional outcome in patients with paragangliomas of the head and neck. The volumetric analysis provides improved evidence for sustained tumor control.
引用
收藏
页码:818 / 823
页数:6
相关论文
共 50 条
  • [21] Revisiting radioresistance: a systematic review of outcomes of Stereotactic radiosurgery (SRS) in functional head and neck paragangliomas
    Onam Verma
    Georgios Mantziaris
    Liza Das
    Jason P. Sheehan
    Manjul Tripathi
    Neurosurgical Review, 48 (1)
  • [22] Stereotactic radiotherapy for head neck cancer
    Mali, Shrikant Balasaheb
    ORAL ONCOLOGY, 2015, 51 (04) : E19 - E20
  • [23] Fractionated stereotactic radiotherapy of glomus Jugulare tumors - Local control, toxicity, symptomatology, and quality of life
    Henzel, Martin
    Hamm, Klaus
    Gross, Markus W.
    Surber, Gunnar
    Kleinert, Gabriele
    Failing, Thomas
    Sitter, Helmut
    Strassmann, Gerd
    Engenhart-Cabillic, Rita
    STRAHLENTHERAPIE UND ONKOLOGIE, 2007, 183 (10) : 557 - 562
  • [24] Impact of adjuvant fractionated stereotactic radiotherapy dose on local control of brain metastases
    Hima B. Musunuru
    Jacob S. Witt
    Poonam Yadav
    David M. Francis
    Aleksandra Kuczmarska-Haas
    Zacariah E. Labby
    Michael F. Bassetti
    Steven P. Howard
    Andrew M. Baschnagel
    Journal of Neuro-Oncology, 2019, 145 : 385 - 390
  • [25] Outcome following radiotherapy for head and neck basal cell carcinoma with 'aggressive' features
    Rishi, Anupam
    Huang, Shao Hui
    O'Sullivan, Brian
    Goldstein, David P.
    Lu, Lin
    Ringash, Jolie
    Waldron, John
    Wells, Woody
    Sun, Alex
    Hope, Andrew
    Chung, Peter
    Giuliani, Meredith
    Spreafico, Anna
    Tong, Li
    Xu, Wei
    Bayley, Andrew
    ORAL ONCOLOGY, 2017, 72 : 157 - 164
  • [26] Impact of Cochlear Dose on Hearing Preservation following Stereotactic Radiosurgery and Fractionated Stereotactic Radiotherapy for the Treatment of Vestibular Schwannoma
    Chung, Lawrance K.
    Ung, Nolan
    Sheppard, John P.
    Thien Nguyen
    Lagman, Carlito
    Choy, Winward
    Tenn, Stephen
    Pouratian, Nader
    Lee, Percy
    Kaprealian, Tania
    Selch, Michael
    De Salles, Antonio
    Gopen, Quinton
    Yang, Isaac
    JOURNAL OF NEUROLOGICAL SURGERY PART B-SKULL BASE, 2018, 79 (04) : 335 - 342
  • [27] Fractionated stereotactic radiotherapy of brainstem metastases - Clinical outcome and prognostic factors
    Kraemer, Anna
    Hahnemann, Laura
    Schunn, Fabian
    Grott, Christoph A.
    Thomas, Michael
    Christopoulos, Petros
    Lischalk, Jonathan W.
    Hoerner-Rieber, Juliane
    Hoegen-Sassmannshausen, Philipp
    Eichkorn, Tanja
    Deng, Maximilian Y.
    Meixner, Eva
    Lang, Kristin
    Paul, Angela
    Weykamp, Fabian
    Debus, Juergen
    Koenig, Laila
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2025, 50
  • [28] Stereotactic radiosurgery vs. fractionated radiotherapy for tumor control in vestibular schwannoma patients: a systematic review
    Persson, Oscar
    Bartek, Jiri, Jr.
    Ben Shalom, Netanel
    Wangerid, Theresa
    Jakola, Asgeir Store
    Forander, Petter
    ACTA NEUROCHIRURGICA, 2017, 159 (06) : 1013 - 1021
  • [29] Role of stereotactic radiotherapy for head neck cancer
    Mali, Shrikant B.
    ORAL AND MAXILLOFACIAL SURGERY-HEIDELBERG, 2025, 29 (01):
  • [30] Role of stereotactic body radiotherapy for symptom control in head and neck cancer patients
    Khan, Luluel
    Tjong, Michael
    Raziee, Hamid
    Lee, Justin
    Erler, Darby
    Chin, Lee
    Poon, Ian
    SUPPORTIVE CARE IN CANCER, 2015, 23 (04) : 1099 - 1103